










A New Wave: Emerging Therapies in the Atopic Dermatitis Pipeline

Generic Drug Name	Mechanism of Action	Route of Administration	Phase of Development	Age Group Being Studied	Developers
Ruxolitinib	JAK1/2 inhibitor	Topical Cream	Phase 3 (completed)	Ages 12+	Incyte/ Novartis 
Tralokinumab	IL-13 inhibitor	Subcutaneous Injection	Phase 3 (completed)	Ages 12+	LEO Pharma 
Baricitinib	JAK1/2 inhibitor	Oral	Phase 3	Ages 18+	Eli Lilly and Company 
Dupilumab	IL-4/IL-13 inhibitor	Subcutaneous Injection	Phase 3	Ages 6 months+	Regeneron-Sanofi 
Lebrikizumab	IL-13 inhibitor	Subcutaneous Injection	Phase 3	Ages 12+	Dermira 
Upadacitinib	JAK1 inhibitor	Oral	Phase 3	Ages 12+	AbbVie 
Abrocitinib	JAK1 inhibitor	Oral	Phase 3	Ages 12+	Pfizer 
Nemolizumab	IL-31 inhibitor	Subcutaneous Injection	Phase 3	Ages 12+	Galderma 
Benralizumab	IL-5 inhibitor	Subcutaneous Injection	Phase 2	Ages 12+	AstraZeneca 
ATI-1777	JAK1/3 inhibitor	Soft Topical	Phase 2	Ages 18+	Aclaris Therapeutics 
Bermekimab	IL-1 α inhibitor	Subcutaneous Injection	Phase 2	Ages 18+	Janssen 
Delgocitinib	JAK inhibitor	Topical Ointment	Phase 2 (Completed) Phase 1	Ages 18+ Ages 2+	LEO Pharma 